抑制肺癌新生血管及其临床应用的研究进展

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Angiogenesis can seriously affect the occurrence and development of tumors.In recent years,with the development of molecular biology,targeting angiogenesis has become a research hotspot for the treatment of non-small cell lung cancer(NSCLC).Blocking the blood supply of tumor cells,making the cells in a state of hypoxia and lack of nutrients,is an effective means to inhibit the growth and proliferation of tumors.Targeting tumor angiogenesis as a target has become a research hotspot,however,the Angiogenesis is extremely complex,and single target blocking therapy often does not solve the underlying problem.Future anti-vascular therapies will focus on multi-target combined blockade.This article reviews the role of several regulatory factors related to tumor angiogenesis and their clinical applications,aiming to provide a reference for the clinical research of lung cancer.

Key words： Non-small cell lung cancer Angiogenesis EGFR-TKI Cyclooxygenase-2 inhibitors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Rui-lian
	ZHANG Qing

Cite this article:

ZHANG Rui-lian,ZHANG Qing. Research progress in inhibiting neovascularization of lung cancer and its clinical application[J]. 中国当代医药, 2018, 25(26): 36-38.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I26/36

[2]	Toomey DP，Murphy JF，Conlon KC.Cox-2，vegf and tumour angiogenesis[J].Surgeon，2009，7：174-180
[3]	Krishna Priya S，Nagare RP，Sneha VS，et al.Tumour angiogenesis-Origin of blood vessels[J].Int J Cancer，2016，139（4）：729-735.
[5]	Geudens I，Gerhardt H.Coordinating cell behaviour during blood vessel formation[J].Development，2011，138：4569-4583.
[6]	席妍，王彦荣，宋阳.非小细胞肺癌组织 CXCR4表达及MVD 的研究[J].中国实验诊断学，2011，15（1）：72-75.
[1]	Van Cutsem E，Lambrechts D，Prenen H，et al.Lessons from the adjuvant bevacizumab trial on colon cancer：what next?[J].J Clin Oncol，2011，29（1）：1-4.
[4]	Fontanini G，Vignati S，Bigini D，et al.Neoangiogenesis：a putative marker of malignancy in non-small-cell lung cancer（NSCLC）development[J].Int J Cancer，1996，67：615-619.
[7]	闵发胜，张宁，杨生斌，等.NSCLC患者外周血淋巴细胞抗癌药敏试验与化疗疗效的相关性[J].华南国防医学杂志，2007，21（4）：19.
[8]	邱敏，梁志清.微血管密度与卵巢癌临床病量参数的联系[J].华南国防医学杂志，2007，21（1）：1.
[9]	Takahashi T，Kozaki K，Yatabe Y，et al.Increased expression of COX-2 in the development of human lung cancers[J].J Environ Pathol Toxicol Oncol，2002，21：177-181.
[10]	Kim HS，Youm HR，LeeJS，et al.Correlation between cyclooxygenase-2 and tumor angiogenesis innon—small cell lung caneer[J]．Lung Cancer，2003，42：163-179.
[11]	Howe LR，Dannenberg AJ.A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer[J].Semin Oncol，2002，29（11）：111-119.
[12]	孙丽梅，赵月，王鲁建，等．非小细胞肺癌中 COX2蛋白对细胞凋亡的抑制作用[J].中国肺癌杂志，2007，10（3）：188-191.
[13]	滕云.环氧化酶-2与非小细胞肺癌研究进展[J].中国临床研究，2011，24（8）：737-738.
[14]	Cianchi F，Cortesini C，Bechi P，et al.Up-regulation of cyclooxygen-ase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer[J].Gastroenterology，2001，121 （6）： 1339-1347．
[15]	Liu R，Xu KP，Tan GS.Cyclooxygenase-2 inhibitors in lung Cancer treatment：bench to bed[J].Eur J Pharmacol，2015，769：127-133.
[16]	张卿，于琳，徐磊，等.选择性COX-2抑制剂联合顺铂对肺癌的协同细胞毒作用及其机制研究[J].内蒙古医学院学报，2009，31（6）：610-615.
[17]	王娜.环氧化酶2抑制剂联合化疗药对人肺癌裸鼠移植瘤生长和淋巴转移的影响[J].中国老年学杂志，2013，33（19）：4794-4796.
[18]	韩志强.选择性环氧化酶-2抑制剂联合放射治疗对肺癌A549细胞作用的实验研究[D].苏州.苏州大学，2009.
[19]	王国栋，党亚正.塞来昔布对肝癌细胞放疗增敏作用研究[J].西北国防医学杂志，2014，35（6）：531-534.
[20]	]Selvaggi G，Novello S，Torri V，et al.Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer[J].Ann Oncol，2004，15（1）：28-32.
[21]	Chiu HC，Chang TY，Huang CT，et al.EGFR and myosin II inhibitors cooperate to suppress EGFR-T790M-mutant NSCLC cells[J].Mol Oncol，2012，6（3）：299-310.
[22]	王亚丽，牟晓燕，白小燕，等.吉非替尼联合塞来昔布对肺腺癌细胞凋亡和 EGFR、COX-2表达的影响[J].山东大学学报（医学版），2009，47（8）：37-41.
[23]	Reckamp KL，Koczywas M，Cristea MC，et al.Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer[J].Cancer，2015，121（18）：3298-3306.
[24]	Lippman SM，Gibson N，Subbaramaiah K，et al.Combined targeting of the epidermal growth factor receptor and cyclooxy-genase-2 pathways[J].Clin Cancer Res，2005，11（17）：6097-6099.